Establishing a Southern Swedish Malignant Melanoma OMICS and Biobank Clinical Capability
News Mar 22, 2013
The objectives and goals of the Southern Swedish Malignant Melanoma (SSMM) are to develop, build and utilize cutting edge biobanks and OMICS platforms to better understand disease pathology and drug mechanisms. The SSMM research team is a truly cross-functional group with members from oncology, surgery, bioinformatics, proteomics, and genomics initiatives. Within the research team there are members who daily diagnose patients with suspect melanomas, do follow-ups on malignant melanoma patients and remove primary or metastatic lesions by surgery. This inter-disciplinary clinical patient care ensures a competence build as well as a best practice procedure where the patient benefits.
This article was published online in Clinical and Translational Medicine, and is free to access.
BC Platforms Announces Collaborations in Multiple Sclerosis ResearchNews
Company's technology and research platforms used to better understand genetic basis of MS.READ MORE
Pathway in Neurons may Contribute to Neurodegenerative DiseaseNews
Pathway has received attention as potential drug target.READ MORE
Evotec Achieves First Milestone in Neurodegeneration Alliance with CelgeneNews
Successful completion of iPSC screening campaign.READ MORE